Gilead: FDA OKs Trodelvy
The FDA has approved Gilead's Trodelvy for two indications, one for monotherapy and the other for combination with pembrolizumab.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.